New Medical Trial Aims to Stop Alzheimer’s Before Symptoms Begin

For many years, medical research into Alzheimer’s disease has focused on finding treatments for patients who are already showing signs of memory loss. However, a new international study is changing this approach by looking at whether the disease can be stopped before it even starts. According to The Guardian Health, a new clinical trial called PrevenTRON is now recruiting healthy middle-aged people to test an experimental drug that may prevent dementia from developing.

Alzheimer’s disease is a serious condition that affects millions of people globally. It is estimated that the disease begins to develop inside the brain up to 10 years before a person starts to notice any memory problems. Currently, the condition affects about one in 14 people over the age of 65, and this number increases to one in six for those over 80. Because the disease often causes brain cells to die over time, scientists are eager to find ways to intervene at an earlier stage.

The PrevenTRON study is looking for 1,600 participants between the ages of 55 and 80 from around the world. In the UK, the Surrey and Borders Partnership NHS foundation trust is leading the recruitment process. The first step for potential participants is a screening to ensure they do not currently have any memory issues. If they pass this stage, they will have a blood test to check for a specific biomarker called p-tau217. A biomarker is a biological sign in the body that can help doctors predict the development of a disease. Previous research suggests that high levels of p-tau217 are linked to a 78% chance of developing cognitive problems within 10 years.

The drug being tested is called trontinemab, which was created by the Swiss pharmaceutical company Roche. This medicine works by attacking amyloid plaques. These are toxic proteins that build up in the brain and eventually kill brain cells. Early research on patients who already had early-stage Alzheimer’s showed that the drug was very effective at clearing these plaques. In fact, the drug removed these harmful proteins in nine out of 10 people within 28 weeks. Now, researchers want to see if the same drug can stop the disease from developing in people who are currently healthy but at risk.

Professor Ramin Nilforooshan, who is the chief investigator for the trial, explained that this study represents a major shift in how scientists think about the disease. He noted that for decades, the focus was only on treating patients after symptoms appeared. By moving the focus to prevention, researchers hope to stop the damage before it becomes permanent. At least 15 hospitals and clinics across the UK are expected to join the study by the end of the year. The trial will last between four and six years, during which time participants will be randomly chosen to receive either the drug or a placebo—a substance with no medicine in it used for comparison.

Despite the excitement surrounding this new study, experts are being careful not to promise too much too soon. Professor Nilforooshan spoke to the Telegraph about the need for caution, noting that the treatment is still experimental. He explained that the trial is not magic and that researchers must wait to see the results to determine if the drug actually works as expected. Because the trial is still in its early stages, it remains a scientific investigation rather than a proven cure.

This study is a significant step forward in understanding how to protect brain health. If the trial is successful, it could change the lives of millions of people who are at risk of developing dementia. For now, the medical community is watching the progress of the PrevenTRON study closely. Those who are interested in participating in the trial can contact the research team at the Surrey and Borders Partnership for more information about the screening process.